KPRX RSI Chart
Last 7 days
14.3%
Last 30 days
9.8%
Last 90 days
-12.5%
Trailing 12 Months
-73.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 | 0 |
2020 | 0 | 0 | 0 | 0 |
2019 | 3.2M | 3.0M | 2.7M | 2.7M |
2018 | 1.3M | 1.4M | 1.7M | 1.7M |
2017 | 839.9K | 753.6K | 554.0K | 407.5K |
2016 | 0 | 453.8K | 568.5K | 683.2K |
2015 | 339.1K | 0 | 0 | 0 |
2014 | 210.4K | 215.0K | 219.7K | 224.4K |
2013 | 0 | 0 | 0 | 205.7K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 29, 2023 | tosca melissa | acquired | - | - | 30,000 | evp finance |
Sep 29, 2023 | daniels eric joseph | acquired | - | - | 62,500 | chief development officer |
Sep 29, 2023 | strem brian m. | acquired | - | - | 75,000 | president and ceo |
Mar 03, 2023 | tosca melissa | acquired | - | - | 2,400 | evp finance |
Mar 03, 2023 | daniels eric joseph | acquired | - | - | 15,600 | chief development officer |
Mar 03, 2023 | strem brian m. | acquired | 59,748 | 3.83 | 15,600 | president and ceo |
Oct 21, 2022 | strem brian m. | acquired | - | - | 12,500 | president and ceo |
Oct 21, 2022 | tosca melissa | acquired | - | - | 2,500 | evp of finance |
Oct 21, 2022 | daniels eric joseph | acquired | - | - | 10,000 | chief development officer |
Feb 10, 2022 | romano sarah | sold (taxes) | -74.52 | 0.69 | -108 | chief financial officer |
Which funds bought or sold KPRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | unchanged | - | 2.00 | 6.00 | -% |
May 15, 2024 | ADAR1 Capital Management, LLC | new | - | 776,600 | 776,600 | 0.18% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 0.34 | 778 | 2,956 | -% |
May 15, 2024 | CAPTRUST FINANCIAL ADVISORS | unchanged | - | 14,688 | 56,480 | -% |
May 15, 2024 | Nantahala Capital Management, LLC | new | - | 1,341,400 | 1,341,400 | 0.08% |
May 15, 2024 | Alyeska Investment Group, L.P. | new | - | 1,553,200 | 1,553,200 | 0.01% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | new | - | 7,308 | 7,308 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -49,070 | - | -% |
May 14, 2024 | Velan Capital Investment Management LP | new | - | 776,600 | 776,600 | 0.35% |
May 14, 2024 | AIGH Capital Management LLC | new | - | 1,623,800 | 1,623,800 | 0.49% |
Unveiling Kiora Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Kiora Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Kiora Pharmaceuticals, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | - | 16,000,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,686,000 | - | 314,500 | 242,012 |
Operating Expenses | 31.1% | 2,777,906 | 2,118,649 | 5,918,568 | 2,633,012 | 1,916,667 | 2,634,998 | 3,703,035 | 2,402,048 | 3,569,442 | 6,370,993 | 3,035,089 | 2,819,504 | 2,010,182 | 1,181,637 | 2,616,607 | 3,451,274 | 1,869,800 | 1,857,360 | 2,489,456 | 3,492,378 | 3,040,330 |
S&GA Expenses | -100.0% | - | 880,550 | 1,415,844 | 1,097,294 | 1,269,458 | 2,777,957 | 2,033,367 | 1,801,878 | 1,664,791 | 1,379,025 | 1,338,616 | 1,305,865 | 1,300,143 | 1,514,514 | 1,118,752 | 1,045,145 | 1,105,904 | 1,135,883 | 1,052,202 | 1,232,677 | 1,202,531 |
R&D Expenses | 34.4% | 1,493,659 | 1,111,645 | 1,085,010 | 1,392,099 | 438,283 | 841,617 | 1,332,153 | 567,227 | 707,928 | 1,001,633 | 1,628,467 | 1,439,922 | 1,280,242 | 1,011,010 | 1,497,855 | 2,406,129 | 763,896 | 721,477 | 1,437,254 | 2,259,701 | 1,837,799 |
EBITDA Margin | 1.5% | -4.53 | -4.60 | -5.03 | -5.05 | -5.07 | -5.08 | -5.18 | -5.18 | -5.18 | -5.18 | -2.53 | -2.53 | -2.53 | -2.54 | - | - | - | - | - | - | - |
Interest Expenses | 290.1% | 223,047 | -117,332 | 49,912 | 45,087 | 33,465 | -716 | 7,861 | 1,237 | 217 | 6,301 | 259 | 2,033 | 686 | 4,186 | - | 109 | 108 | 108 | 128 | 304 | 304 |
EBT Margin | 0% | -4.63 | -4.63 | -5.10 | -5.10 | -5.10 | -5.10 | -5.20 | -5.20 | -5.20 | -5.20 | -2.55 | -2.55 | -2.55 | -2.55 | - | - | - | - | - | - | - |
Net Income | 693.0% | 13,453,207 | -2,268,606 | -5,762,941 | -2,613,813 | -1,868,536 | -2,498,446 | -5,119,339 | -2,400,811 | -3,565,014 | -6,182,222 | -3,034,830 | -2,543,015 | -2,010,618 | -1,185,595 | -2,701,846 | -3,428,387 | -1,837,272 | 870,809 | -2,528,005 | -3,123,836 | -2,780,255 |
Net Income Margin | 122.4% | 1.05 | -4.66 | -4.74 | -4.50 | -4.43 | -5.06 | -6.43 | -5.65 | -5.71 | -5.13 | -3.27 | -2.88 | -2.58 | -2.55 | - | - | - | - | - | - | - |
Free Cashflow | 627.8% | 13,624,855 | -2,581,341 | -2,521,097 | -1,384,919 | -3,069,594 | -2,129,000 | -2,967,807 | -2,498,940 | -2,832,386 | -2,919,668 | -2,270,107 | -2,921,310 | -2,628,170 | -1,709,467 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 209.5% | 42,440 | 13,712 | 15,896 | 19,885 | 16,528 | 18,678 | 17,662 | 15,463 | 17,636 | 20,130 | 25,493 | 18,100 | 20,621 | 15,304 | 9,245 | 10,967 | 12,187 | 10,113 | 8,868 | 10,896 | 12,439 |
Current Assets | 606.7% | 33,482 | 4,738 | 6,983 | 9,023 | 5,618 | 7,681 | 6,624 | 4,380 | 6,550 | 8,991 | 11,870 | 4,415 | 6,991 | 1,726 | 3,498 | 5,197 | 6,394 | 4,324 | 3,113 | 5,128 | 6,659 |
Cash Equivalents | 1151.2% | 31,280 | 2,500 | 5,400 | 7,952 | 3,426 | 5,965 | 4,851 | 2,477 | 5,112 | 7,900 | 11,152 | 3,708 | 6,655 | 1,231 | 2,976 | 4,734 | 5,923 | 3,822 | 2,500 | 4,510 | 5,901 |
Net PPE | 60.2% | 13.00 | 8.00 | 39.00 | 45.00 | 51.00 | 55.00 | 59.00 | 63.00 | 67.00 | 74.00 | 79.00 | 84.00 | 84.00 | 31.00 | 11.00 | 14.00 | 16.00 | 17.00 | 24.00 | 30.00 | 37.00 |
Goodwill | - | - | - | - | - | - | - | - | - | - | - | 3,485 | 3,485 | 3,485 | 3,631 | 1,526 | 1,526 | 1,526 | 1,526 | 1,526 | 1,526 | 1,526 |
Liabilities | -0.9% | 7,536 | 7,602 | 7,792 | 6,243 | 6,372 | 7,271 | 7,141 | 6,701 | 6,378 | 5,551 | 8,145 | 7,646 | 7,936 | 5,574 | 3,284 | 3,169 | 2,870 | 3,490 | 3,656 | 2,424 | 2,400 |
Current Liabilities | -2.5% | 1,593 | 1,634 | 2,101 | 1,883 | 2,156 | 3,272 | 2,994 | 2,857 | 2,521 | 1,610 | 1,959 | 1,436 | 1,426 | 1,985 | 930 | 816 | 794 | 1,415 | 2,176 | 944 | 920 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 278 | 278 | 278 | 278 | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | 278 | 278 | 278 | 278 | - | - | - | - | - |
Shareholder's Equity | 471.3% | 34,904 | 6,110 | 8,104 | 13,642 | 10,156 | 11,408 | 10,521 | 8,762 | 11,258 | 14,579 | 20,507 | 13,680 | 15,985 | 9,730 | 5,961 | 7,798 | 9,318 | 6,622 | 5,212 | 8,472 | 10,039 |
Retained Earnings | 9.2% | -133,500 | -147,000 | -144,700 | -138,900 | -136,300 | -134,462 | -131,965 | -126,845 | -124,444 | -120,879 | -116,355 | -113,388 | -110,919 | -107,108 | -105,923 | -103,916 | -102,199 | -100,246 | -97,545 | -94,116 | -92,279 |
Additional Paid-In Capital | 9.9% | 168,430 | 153,192 | 153,001 | 152,744 | 146,683 | 146,035 | 142,739 | 135,701 | 135,634 | 135,542 | 133,638 | 123,787 | 123,524 | 116,784 | 111,716 | 111,528 | 111,331 | 106,689 | 102,588 | 101,996 | 101,729 |
Shares Outstanding | 240.7% | 26,256 | 7,706 | 7,689 | 6,911 | 1,919 | 1,796 | 43,163 | 13,061 | 316 | 317 | 268 | 185 | 184 | 139 | - | - | - | - | - | - | - |
Float | - | - | - | - | 4,763 | - | - | - | 6,118 | - | - | - | 45,594 | - | - | - | 16,290 | - | - | - | 7,795 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 627.8% | 13,625 | -2,581 | -2,521 | -1,384 | -3,069 | -2,129 | -2,967 | -2,498 | -2,832 | -2,919 | -2,270 | -2,915 | -2,570 | -1,709 | -1,740 | -1,467 | -2,400 | -2,586 | -1,998 | -1,422 | -2,146 |
Share Based Compensation | -3.8% | 175 | 182 | 265 | 172 | 136 | 45.00 | 130 | 71.00 | 216 | 213 | 149 | 263 | 217 | 193 | 188 | 197 | 146 | 203 | 180 | 236 | 233 |
Cashflow From Investing | - | - | - | - | - | - | - | - | - | 6.00 | -93.15 | - | -5.75 | -58.12 | - | - | - | - | - | - | - | - |
Cashflow From Financing | 3234.7% | 15,248 | -486 | - | 5,939 | 513 | 3,243 | 5,378 | - | - | -212 | 9,756 | - | 8,039 | 218 | - | 278 | 4,501 | 3,908 | -15.75 | 30.00 | -1.57 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue: | ||
Collaboration Revenue | $ 16,000,000 | $ 0 |
Total Revenue | 16,000,000 | 0 |
Operating Expenses: | ||
General and Administrative | 1,296,441 | 1,269,458 |
Research and Development | 1,493,659 | 438,283 |
Change in Fair Value of Contingent Consideration | (12,194) | 208,926 |
Total Operating Expenses | 2,777,906 | 1,916,667 |
Operating Income (Loss) | 13,222,094 | (1,916,667) |
Other Income, Net: | ||
Interest Income, Net | 223,047 | 33,465 |
Other Income, Net | 8,066 | 14,666 |
Total Other Income, Net | 231,113 | 48,131 |
Net Income (Loss) | $ 13,453,207 | $ (1,868,536) |
Net Loss per Common Share - Basic (in usd per share) | $ 0.52 | $ (1.00) |
Weighted Average Shares Outstanding - Basic (in shares) | 25,936,163 | 1,863,466 |
Net Loss per Common Share - Diluted (in usd per share) | $ 0.38 | $ (1.00) |
Weighted Average Shares Outstanding - Diluted (in shares) | 35,025,494 | 1,863,466 |
Other Comprehensive Income (Loss): | ||
Net Income (Loss) | $ 13,453,207 | $ (1,868,536) |
Foreign Currency Translation Adjustments | (81,573) | (32,671) |
Comprehensive Income (Loss) | $ 13,371,634 | $ (1,901,207) |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and Cash Equivalents | $ 31,276,330 | $ 2,454,684 |
Prepaid Expenses and Other Current Assets | 206,671 | 233,382 |
Collaboration Receivables | 189,905 | 0 |
Tax Receivables | 1,808,787 | 2,049,965 |
Total Current Assets | 33,481,693 | 4,738,031 |
Non-Current Assets: | ||
Property and Equipment, Net | 12,918 | 8,065 |
Restricted Cash | 4,084 | 4,267 |
Intangible Assets and In-Process R&D, Net | 8,807,600 | 8,813,850 |
Operating Lease Assets with Right-of-Use | 94,298 | 106,890 |
Other Assets | 39,414 | 40,767 |
Total Assets | 42,440,007 | 13,711,870 |
Current Liabilities: | ||
Accounts Payable | 323,062 | 206,260 |
Accrued Expenses | 1,222,078 | 1,380,666 |
Operating Lease Liabilities | 47,851 | 47,069 |
Total Current Liabilities | 1,592,991 | 1,633,995 |
Non-Current Liabilities: | ||
Contingent Consideration | 5,116,765 | 5,128,959 |
Deferred Tax Liability | 779,440 | 779,440 |
Operating Lease Liabilities | 46,448 | 59,822 |
Total Non-Current Liabilities | 5,942,653 | 5,968,221 |
Total Liabilities | 7,535,644 | 7,602,216 |
Commitments and Contingencies (Note 8) | ||
Stockholders’ Equity: | ||
Preferred Stock | 4 | 4 |
Common Stock, $0.01 Par Value: 50,000,000 shares authorized; 26,256,197 and 7,705,640 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 262,584 | 77,078 |
Additional Paid-In Capital | 168,429,797 | 153,192,228 |
Accumulated Deficit | (133,523,648) | (146,976,855) |
Accumulated Other Comprehensive Loss | (264,374) | (182,801) |
Total Stockholders’ Equity | 34,904,363 | 6,109,654 |
Total Liabilities and Stockholders’ Equity | $ 42,440,007 | $ 13,711,870 |